3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
6
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms
2
Kidney Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Skin Neoplasms
1
Recurrence
1
Radiation Injuries
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Pleural Effusion, Malignant
1
Platinum Resistant Ovarian Cancer
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Melanoma
1
Lymphopenia
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Hot Flashes
1
Hodgkin Disease
1
Gangliosidosis, GM1
1
Gangliosidoses
1
Fatigue
1
Interventions
BNT162 Vaccine
2
2019-nCoV Vaccine mRNA-1273
2
tocilizumab
1
sotrovimab
1
heterologous prime boost COVID-19 vaccination
1
cilgavimab and tixagevimab drug combination
1
Therapeutics
1
Specimen Handling
1
Sodium Chloride
1
Radiotherapy
1
Losartan
1
Janus Kinase Inhibitors
1
Ivermectin
1
Interleukin-7
1
Hydroxychloroquine
1
HuMax-IL8
1
Ad26COVS1
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
COVID-19
×
Sodium Chloride
×
Clear all
NCT04426201
2024-04-11
ILIAD-7-US-O
Revimmune
Phase 2
Terminated
10 enrolled